Older adults and those with metabolic conditions such as obesity also received significant benefits against stroke and death.

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works alone rather than in combination with another drug called ritonavir. But ...

Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission.

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving Long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3. “This is ...

they have 1 or more risk factors for progression to severe COVID‑19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for ...